

ASX Announcement and Media Release

Tuesday 16 December 2003

SciGen Limited

SCI GEN ENTERS RECOMBINANT HUMAN INSULIN MARKET IN CHINA

SciGen Limited ("SciGen") announced today that the company has entered into a commercialisation agreement for the marketing, sale and distribution of SciGen's recombinant human insulin ("SciLin") throughout China.

The agreement is exclusive for 6 years and requires SciGen's partner to only sell SciLin during the term.

SciGen's partner is a company of substance with considerable experience over a number of years in the diabetes market in China.

The commercialisation agreement contains minimum order provisions which is expected to generate a minimum US\$21.0M in revenue for SciGen over the three years following registration. SciGen's expert Regulatory Affairs team will work with SciGen's partner and the Chinese Authorities to move registration forward as quickly as possible. It is anticipated that the registration of SciLin in China will take about 6-12 months.

The commercialisation agreement also includes SciGen's needle free injection device- Scitojet. This completely needle free device will be used in China for the administration of SciLin.

The relationship that has been formed has the potential to cover other products in SciGen's portfolio in due course.

The World Health Organisation (WHO) reports that after India, China has the largest number of patients with diabetes in the World. WHO estimates that in the year 2000 there were 20.7 million people with diabetes in China. This number grew by approximately 1 million people per year over the previous 5 years. The prevalence of diabetes had grown from 2.0% to 2.4% of the population during the same period.

This agreement is another example of SciGen's demonstrated ability to work in the Asia Pacific Region to establish partnerships in order to maximise sales and marketing opportunities for SciGen's portfolio of products. Moreover, it continues to consolidate SciGen's revenue streams going forward.

About SciGen

SciGen Ltd is a progressive biotechnology/biopharmaceutical company involved in co-developing and marketing genetically engineered biopharmaceutical products for human healthcare. SciGen focuses in the areas of gastroenterology, endocrinology and immunology. Its product portfolio includes vaccines and therapeutics.

SciGen has acquired the rights to manufacture, distribute and market biopharmaceutical products under exclusive licensing arrangements. SciGen's portfolio currently includes proprietary biotechnology-derived products, and biogeneric products, which allows for faster entry into the market, as the biogeneric products have undergone much of the clinical development and trials required to bring new drugs to market. This minimises the risks associated with early stage product development. SciGen currently undertakes R&D activities in collaboration with strategic partners and institutions.

SciGen's major strength lies in its ability to recognise the potential of new products in their early stages of development. Through joint collaboration with its strategic partners, SciGen uses its extensive expertise in regulatory and clinical environments, in conjunction with marketing and promotional infrastructure, to bring to market products which will have significant long-term benefit.

SciGen's business was established in 1988. SciGen is a Singaporean biotechnology company, publicly listed on the Australian Stock Exchange (ASX code SIE). SciGen's headquarters is in Singapore and it also has offices in Australia, USA, Korea, Vietnam, Hong Kong and Philippines and partners in India, Indonesia, Israel, Poland and the Netherlands.

=====ENDS=====

Media enquiries

Mark Compton

Managing Director & CEO

Telephone: +61 2 9234 1700

Web: www.scigen.com.au